GLP-1s are prescription medications; a provider must evaluate you and document a clinical basis.
“Prescription required” means a licensed provider must evaluate you and document medical appropriateness before you can receive the medication. For compounded GLP-1 after the shortage, that documentation also needs a clinical reason the FDA-approved product cannot be used — cost alone does not qualify.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.